Richard Ascione’s Biography

CEO, President OnkoLogix USA LTD and ImmunoLogix LTD USA and CSO of OnkoRx in Beijing China

Director, Equity Research, Fairlook Investment Advisors LLC.

MD/PhD from New York University – Bellevue

OnkoLogix LTD and OnkoRx are innovative cancer therapeutic companies that are currently developing novel anti-cancer biologics for Gastric Cancer and other malignancies. ImmunoLogix LTD is a unique Biotech Company developing innovative approaches to developing vaccines and immunologicals for a variety of infectious diseases, including the Pandemic Influenzas and other viral diseases. Prior to this activity Dr. Ascione was active in the Biopharmaceutical Industry as: Consultant and CSO for ViRexx Medical Corp., Vice President, Research, of Aphton Biopharmaceutical Corporation, Prior to his Industry career, Dr. Ascione was a tenured professor in the Department of Experimental Oncology and served as the Associate Director of the Center for Molecular and Structural Biology at the Hollings Cancer Center and the Medical University of South Carolina, respectively, in Charleston, South Carolina. Prior to his academic career, Dr. Ascione was with the National Cancer Institute (NCI) of the National Institutes of Health (NIH), where he served as Deputy Chief of NCI’s Laboratory of Molecular Oncology working on the pioneering investigations of the role of oncogenes in human malignancies.